Aracari Biosciences

The paper describes a modular, two-layer microfluidic system developed to generate large-scale perfused microvascular networks in vitro.

Aracari offers services in vascular biology, tumor models, and oncology testing, including leukocyte extravasation and vasoreactive micro-organs.

Aracari’s platforms use self-assembled human blood vessels to support tissue growth and deliver drugs and cell therapies. The page notes that therapeutics, including small molecules, antibodies, and immune cells, are commonly delivered through blood vessels.

Aracari’s technology focuses on vascularized microtissues. The page states that blood vessels help pattern tissues and supply nutrients, and that therapeutics reach tissues through vessels.

The text states that around 95% of anti-cancer drugs that show promise in preclinical studies fail to gain FDA approval. It describes the vascularized micro-tumor as a three-dimensional tumor-on-a-chip model.

The text reports that the inflation-adjusted cost of bringing a new drug to market has exceeded $2.5 billion and doubles every nine years. It states that 9.6% of drugs entering phase I clinical trials gain FDA approval.

The research presents a 3D in vitro model of vascularized human bone marrow niches, developed using microfluidic and stem cell technologies.

Aracari’s platforms have been validated, and related publications appear in peer-reviewed journals categorized by subject area.

Aracari Biosciences announced that co-founder Dr. Steve George would present on microphysiological systems for immune cell trafficking and capture at the first MPS World Summit in 2022.

Aracari Biosciences won the Startup World Cup Southern California in 2022. Pegasus Tech Ventures organized the event with the LA Venture Association and Pepperdine University Graziadio Business School.

Aracari Biosciences’ Chief Scientific Officer, Dr. Chris Hughes, spoke at BioInsights’ Immuno-Oncology Insights series on vascularized micro-tumor chips for mimicking clinical drug responses.

Aracari Biosciences, Inc. (“Aracari”) announced that it has received a grant from the National Institute of Health to further develop Aracari’s proprietary human bone marrow technology that models in vivo drug responses.

Aracari Biosciences accepts applications from qualified candidates. Applicants can send a CV and Statement of Interest to info@aracaribio.com.

Abraham P. Lee is a professor in the Biomedical Engineering Department with a courtesy appointment in Mechanical and Aerospace Engineering at the University of California, Irvine. Lee’s lab focuses on microfluidic platforms for point-of-care and molecular diagnostics, sample preparation and liquid biopsy, artificial cell vesicles for theranostics, cell engineering, and single-cell processing.

Christopher C.W. Hughes is a professor of Molecular Biology & Biochemistry and Biomedical Engineering at UC Irvine. His appointments have included department chair, director of the Edwards Lifesciences Center for Advanced Cardiovascular Technology, and co-director of the Onco-Imaging and Biotechnology Program.

G. Wesley Hatfield has worked in academia and entrepreneurship, advocated technology transfer, and served on UCI, UC system-wide, state, and national committees. He has founded and invested in several biotechnology companies.

Heidi Zamora holds a Master of Science in Bioengineering from the University of California at Riverside. At Aracari, she has delivered contract research projects testing the toxicity and efficacy of biotherapeutics using the company’s vascularized microphysiological systems.

Aracari tests therapies on tissues grown in its organ and tumor chips to assess efficacy and safety. The company’s microfluidic, vascularized chips were developed by its scientific founders over two decades.

Aracari offers vascularized microphysiological systems for drug testing.

Aracari's platforms use self-assembled human blood vessels to support tissue growth. Therapeutics, including small molecules, antibodies, and immune cells, are delivered through blood vessels.

Aracari Biosciences’ privacy policy describes the handling and protection of personal information provided through its website.

Aracari Biosciences’ Terms of Use apply to its website and its contents and information, as well as other websites or mobile applications operated by or associated with the company.